3 completed, 1 terminated. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Terminated 1 |
Follow ibrexafungerp: new trials by email Literature Review of ibrexafungerp trials Research Report on ibrexafungerp
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis SCY-078, Voriconazole, Oral Placebo Tablets - Invasive Pulmonary Aspergillosis | Phase 2 | Terminated | Scynexis, Inc. | 22 | 2019-01-22 | 2024-08-09 |
| Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis Fluconazole, SCY-078 - Candida Vulvovaginitis | Phase 2 | Completed | Scynexis, Inc. | 186 | 2017-08-01 | 2021-08-12 |
| Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis SCY-078, Fluconazole - Vulvovaginal Candidiasis | Phase 2 | Completed | Scynexis, Inc. | 96 | 2015-11-01 | 2019-07-12 |
| Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis SCY-078, Fluconazole, Micafungin - Mycoses, Candidiasis, Invasive | Phase 2 | Completed | Scynexis, Inc. | 27 | 2014-09-01 | 2024-06-25 |
Candidiasis, Vulvovaginal (2) · Aspergillosis (1) · Candidemia (1) · Candidiasis, Invasive (1) · Invasive Pulmonary Aspergillosis (1) · Mycoses (1)
Scynexis, Inc. (4)
United States (3) · Germany (2) · Belgium (1) · Canada (1) · Dominican Republic (1) · El Salvador (1) · Guatemala (1) · Honduras (1) · South Africa (1)
David Angulo, MD (4)
2018 (1)